Navigation Links
Volcano Reports Third Quarter Results
Date:11/4/2013

g Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding Volcano's expected revenues, revenue growth, margins, financial results and foreign currency exchange rates for the quarter and year ended December 31, 2013, and the calendar year 2014, the benefits of the resource reprioritization described above, its growth and other strategies and ability to execute on those strategies, competitive positioning, target markets, development of its base business and pipeline, benefits from recent acquisitions and benefits from its products and technologies. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause Volcano's actual results to differ materially and adversely from statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the risk that Volcano's revenue, expense, earnings, earnings per share, margin or other projections may turn out to be inaccurate or Volcano may encounter unanticipated difficulty in achieving these projections; global and regional macroeconomic conditions, generally, and in the medical device and telecom industries specifically; current exchange rate fluctuations; the effect of competitive factors and the company's reaction to those factors; purchasing decisions with respect to the company's products; the pace and extent of market adoption of the company's products and technologies; uncertainty in the process of obtaining regulatory approval or clearances for Volcano's products or devices; the success of Volcano's growth and other strategies, including the integration of recently-acquired businesses and our ability to integrate businesses from future acquisitions; risks associated with Volcano's international operations; timing and achievement of product development milestones; outcome of ongoing or future litigation; investigations an
'/>"/>
SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
2. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
3. Volcano Corporation Presentation At Jefferies Conference To Be Webcast
4. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
5. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, Inc. ... today announced that the Food and Drug Administration ("FDA"), ... comments on RCP,s Investigational New Drug ("IND") application before ... in the US. Dr. Chris Chapman ... and comments on our IND. When we receive the ...
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Four studies highlighting late-breaking research advances in the treatment ... at the 50th Annual Meeting of the American Society of ... Results from a study examining the ability of ... the inner lining of blood vessels, in patients with sickle ...
... at ASH Annual Meeting- , , ... announced results of a randomized phase III study presented ... of Hematology. The study in adult patients with hematological ... syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma ...
Cached Medicine Technology:Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 2Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 3Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 4Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 5Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 6Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 7Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 8Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 9Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5
(Date:7/14/2014)... Carepoint has been designed specifically to facilitate ... intuitive interface for recording, sending, displaying and receiving ... reporting features. , Hall mc - an Ontario-based ... Rebecca de Witte to create this exciting new ... Carepoint provides seamless, real-time communication between the ...
(Date:7/14/2014)... COPENHAGEN Participation in activities that promote mental ... may help protect against the development of Alzheimer,s ... new research reported today at the Alzheimer,s Association ... , Research reported at AAIC 2014 also showed ... post-traumatic stress disorder (PTSD) may increase dementia ...
(Date:7/14/2014)... 2014 Spine Team Texas ... care—from diagnosis to treatment and recovery. Currently all physical ... in or training for certification in The McKenzie Method. ... completed the extensive program. , “We require certification of ... results in better outcomes for spine pain patients,” said ...
(Date:7/14/2014)... July 14, 2014 Cadeon Associates ... Turning Information into Money,” today announced that it ... global program that helps partners resell, deploy, and ... Spotfire® analytics platform. TIBCO Software Inc. is a ... including TIBCO Spotfire analytics, providing businesses the ability ...
(Date:7/13/2014)... Recently, TopDresses100.com, a popular dress company in the ... multi-colored Quinceanera dresses to its product line. According ... outfits are guaranteed to be quality made. Now, they ... , TopDresses100.com has a wide variety of elegant dresses ... are in stock and ready to ship. As an ...
Breaking Medicine News(10 mins):Health News:Home Health Care Professional and Marketing Firm Team Up to Create New Homecare Communication App 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 3Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 4Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 6Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 2Health News:Spine Team Texas’ Physical Therapists Complete The McKenzie Method Training and Certification 3Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 2Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 3Health News:Cheap Multi-colored Quinceanera Dresses From TopDresses100.com 2
... of different alcoholic beverages and drinking behaviour on the risk ... and Cohort of Swedish Men, to study the association between ... acute pancreatitis. In total, 84,601 individuals, aged 46-84 years, ... 513 developed acute pancreatitis. There was a doseresponse association ...
... Aug. 11 (HealthDay News) -- The HIV infection rate among ... of AIDS is 10 to 20 times greater than in ... Two percent of poor heterosexuals in those cities have ... Prevention researchers, analysis of National HIV Behavioral Surveillance System data. ...
... (WASHINGTON, August 11, 2011) According to a study ... of the American Society of Hematology (ASH), researchers ... drug that releases stem cells from the bone marrow into ... at risk for later development of abnormalities involving loss or ...
... THURSDAY, Aug. 11 (HealthDay News) -- Symptoms of Alzheimer,s ... 80, according to a new study that examined the ... The study included 105 Alzheimer,s patients and 125 ... 60 to 75 (young-old) and those 80 and older ...
... Mann HealthDay Reporter , WEDNESDAY, Aug. 10 (HealthDay ... people with an irregular heartbeat may give the old standby, ... an erratic heartbeat known as atrial fibrillation are at increased ... such as a blood clot. For this reason, they have ...
... release is available in French . , ROCKVILLE, ... Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a ... (TB) vaccine that involves people living with the human immunodeficiency ... sites in Senegal and South Africa with primary funding support ...
Cached Medicine News:Health News:Alcohol consumption in relation to acute pancreatitis 2Health News:Poor, Urban Heterosexuals at High Risk of HIV: CDC 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 3Health News:Alzheimer's Harder to Detect in the Very Old 2Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 2Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 3Health News:Study Pits New Blood Thinner Against Warfarin For Irregular Heartbeat 4Health News:New TB vaccine enters proof-of-concept trial in people living with HIV 2Health News:New TB vaccine enters proof-of-concept trial in people living with HIV 3
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Intermittent catheter - Ready-to-Use Sterile, Enclosed System...
... The VerifyNow (Ultegra) System is ... which measures platelet induced aggregation as ... system consists of an instrument, a ... assay device contains reagents based on ...
... The Model 700 Whole Blood/Optical Lumi-Aggregometer available ... This new Aggregometer measures platelet function on ... blood or optical density in plasma with ... method. The Model 700 Aggregometer also has ...
Medicine Products: